Work

ACCURACY a phase (P) II trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): Preliminary safety and efficacy data

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz252.040

Authors: R. Ferrarotto, A. Ho, L.J. Wirth, J. Muzaffar, C. Rodriguez, E. Dekel, R.M. Walker, C. Nadri-Shay, A. Vergara-Silva

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University, Massachusetts General Hospital, Moffitt Cancer Center, University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Salivary Gland Tumors Diagnosis and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics, Eisai, Astellas Pharma, Sun Pharma, Genentech, Allos Therapeutics, Sanofi Genzyme, Ignyta, Daiichi Sankyo Europe

OpenAlex ID: W2977468749

FWCI: 1.204

Cites:

Cited by: 6

Related to: 10